Ax-003/Arimidex (Anastrozole) in the adjuvant therapy of early breast cancer - Ax-003

Study identifier:Ax-003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Postmenopausal women with early hormone-receptor positive breast cancer/no metastasis

Medical condition

Breast Cancer

Phase

Healthy volunteers

Study drug

Anastrozole

Sex

Female

Actual Enrollment

1600

Study type

Observational

Age

N/A

Date

Study Start Date: 01 May 2005

Primary Completion Date: -

Study Completion Date: 01 Mar 2007

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Mar 2008 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
1 all patients treated with Anastrozole	-

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

+49 (0) 800 22 88 66 0

info@astrazeneca.de

Investigators

Principal Investigator

H Brasch

AstraZeneca Germany